Claims for Patent: 12,133,914

Summary for Patent: 12,133,914

Title:	Hydrocortisone oral liquid formulations
Abstract:	Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.
Inventor(s):	Danka Radosavljevic, Sean Brynjelsen, Romona BHATTACHARYA, Kalyan Kathala
Assignee:	Eton Pharmaceuticals Inc , Tulex Pharmaceuticals Inc
Application Number:	US18/443,889
Patent Claims:	1. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a liquid pharmaceutical composition, wherein the liquid pharmaceutical composition is an oral liquid that comprises: hydrocortisone or a pharmaceutically acceptable salt thereof; and a nonaqueous liquid carrier, wherein the nonaqueous liquid carrier is present in the liquid pharmaceutical composition in an amount of from about 70% weight by weight (% wt) to about 99.9% wt; wherein the liquid pharmaceutical composition contains less than 5% wt of water; and wherein the disease or condition comprises endocrine disorders. 2. The method of claim 1, wherein the hydrocortisone or a pharmaceutically acceptable salt thereof is present in the liquid pharmaceutical composition in an amount of about 1 mg/mL. 3. The method of claim 1, wherein the hydrocortisone or a pharmaceutically acceptable salt thereof is present in the liquid pharmaceutical composition in an amount of about 0.01% weight by volume (% w/v) to about 10% w/v. 4. The method of claim 1, wherein the liquid pharmaceutical composition comprises hydrocortisone free base. 5. The method of claim 1, wherein the nonaqueous liquid carrier comprises propylene glycol, glycerin, polyethylene glycol (PEG), alcohol, or a combination thereof. 6. The method of claim 1, wherein the liquid pharmaceutical composition comprises a preservative, and wherein the preservative comprises an antimicrobial agent, a chelating agent, or an antioxidant, or any combinations thereof. 7. The method of claim 1, wherein the administering comprises administering orally or through a nasogastric, jejunostomy, or gastrostomy tube. 8. The method of claim 1, wherein the endocrine disorders comprise adrenal insufficiency. 9. The method of claim 1, wherein the endocrine disorders comprise pediatric adrenal insufficiency. 10. The method of claim 1, wherein the subject is not older than 17 years in age. 11. The method of claim 1, wherein the subject is an adult. 12. The method of claim 1, wherein the endocrine disorders comprise primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, non-suppurative thyroiditis, or hypercalcemia associated with cancer. 13. The method of claim 1, wherein the endocrine disorders comprise primary or secondary adrenocortical insufficiency. 14. The method of claim 1, further comprising administering an additional therapy or treatment regimen. 15. The method of claim 14, wherein the additional therapy or treatment regimen comprises an additional corticosteroid. 16. The method of claim 14, wherein the additional therapy or treatment regimen comprises a mineralocorticoid. 17. The method of claim 1, wherein the administering comprises providing from about 0.1 mg to about 500 mg of hydrocortisone or a pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein the administering comprises providing a dose of hydrocortisone or a pharmaceutically acceptable salt thereof from about 1 mg/m2/day to about 50 mg/m2/day. 19. The method of claim 1, wherein the endocrine disorders comprise primary adrenocortical insufficiency. 20. The method of claim 1, wherein the endocrine disorders comprise secondary adrenocortical insufficiency.